Avacta Group PLC Result of General Meeting (9447Q)

TIDMAVCT

RNS Number : 9447Q

Avacta Group PLC

24 June 2020

24 June 2020

Avacta Group plc

("Avacta", "the Group" or "the Company")

Result of General Meeting

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that at the general meeting held earlier today all resolutions were duly passed.

ADMISSION

Application has been made for the 13,645,718 ordinary shares of 10 pence each ("Ordinary Shares") to be admitted to trading on AIM ("Admission"). It is expected that Admission will become effective and trading in the Ordinary Shares will commence on or around 8.00 a.m. on 25 June 2020.

Following Admission, the Company will have 248,797,815 Ordinary Shares in issue and shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure Guidance and Transparency Rules.

- Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                              Tel: [phone] 
  Alastair Smith, Chief Executive Officer       www.avacta.com 
  Tony Gardiner, Chief Financial Officer 
 finnCap Ltd (Nominated Adviser and Joint      Tel: [phone] 
  Broker)                                       www.finncap.com 
  Geoff Nash / Giles Rolls / Teddy Whiley 
  - Corporate Finance 
  Tim Redfern - E CM 
 Zeus Capital Limited (Joint Broker)           Tel: [phone] 
  John Goold / Rupert Woolfenden - Corporate    www.zeuscapital.co.uk 
  Broking 
 
   Yellow Jersey PR (Financial Media and         Tel: [phone] 
   IR)                                           [e-mail] 
   Sarah Hollins 
   Henry Wilkinson 
                                                 Tel: [phone] 
   Zyme Communications (Trade and Regional       [e-mail] 
   Media) 
   Katie Odgaard 
 

About Avacta Group plc - https://www.avacta.com

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer(R) biotherapeutics and pre|CISION(TM) tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Avacta's pre|CISION targeted chemotherapy platform, releases active chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thereby improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic later in 2020 or early 2021.

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a deal with LG Chem worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and has established a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ROMUSRRRRVUNUAR

(END) Dow Jones Newswires

June 24, 2020 06:15 ET (10:15 GMT)